Key Points for Registration Review and Quality Management of HIV1/2 Urine Antibody Test Kit (Colloidal Gold Method)

Registration Review and Standard Basis

The Human Immunodeficiency Virus (HIV1/2) Urine Antibody Detection Kit (Colloidal Gold Method) is a Class III in vitro diagnostic reagent and must undergo registration review by the National Medical Products Administration. The application materials shall include product technical requirements, analytical performance evaluation, stability studies, clinical evaluation reports, etc. The analytical performance evaluation shall cover indicators such as sensitivity, specificity, cross-reactivity (e.g., interfering substances, antibodies to other pathogens), and precision. Clinical evaluation typically involves comparison with marketed products of the same type or reference methods, and samples shall cover patients with different HIV subtypes and different disease stages. In addition, the product instructions must clearly state the intended use, detection principle, limitations, and methods for result interpretation.

Production Quality Management and Control

The production of such kits shall comply with the Good Manufacturing Practice for Medical Devices, with strict control of batch-to-batch consistency of raw materials (e.g., colloidal gold particles, antibodies/antigens, nitrocellulose membranes, etc.). Key processes include preparation of gold conjugates, membrane strip coating, assembly, and packaging. Each batch of products shall undergo release testing, including appearance, membrane strip width, liquid migration speed, and testing of positive and negative reference materials. Environmental cleanliness shall meet the corresponding grade requirements to prevent cross-contamination. Enterprises shall establish safety management procedures for hazardous biological agents (e.g., inactivated virus in positive controls).

Regulatory Considerations in Clinical Use

In actual use, primary healthcare institutions and self-testing users need to pay attention to the storage conditions of the kit (e.g., 2–30°C, protected from light), expiration date, and lot number information. The state requires such products to continue shelf-life stability tracking after marketing. For positive and suspicious results, users are advised to promptly go to designated hospitals for confirmatory testing and counseling. Regulatory authorities will periodically conduct unannounced inspections and sampling testing to ensure that marketed products continue to meet technical requirements.